Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study
Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · 20.11.2026 · 22 (5)
DOI: 10.48036/hbvf7f59 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, online erschienen am 20.11.2026. Verfasst von Muhammad Ammar Khan und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction/ background: Overactive bladder (OAB) impairs quality of life, and antimuscarinic agents remain the mainstay of its drug treatment. Oxybutynin is non-selective and frequently causes anticholinergic adverse effects, whereas solifenacin is relatively M3-selective; local comparative data on their efficacy and tolerability are limited.
Objective
To compare the efficacy and adverse effects of solifenacin and oxybutynin in patients with overactive bladder (OAB). Study Design and Setting: Prospective cohort study; Department of Physical Medicine and Rehabilitation, Armed Forces Institute of Rehabilitation Medicine (AFIRM), Rawalpindi, Pakistan, from July 2026 till September 2026 (ERC Case No. 01/2025). Methodology: After ethical approval, 170 patients aged 18–65 years with OAB diagnosed by International Continence Society criteria and symptoms for ≥3 months were enrolled by non-probability consecutive sampling. Patients were grouped according to the drug prescribed by the treating physician in routine care: Group A (n=85) received solifenacin 5 mg once daily and Group B (n=85) received immediate-release oxybutynin 5 mg three times daily, for 3 months. Daytime frequency, urgency, nocturia and urge incontinence episodes (recorded in a voiding diary kept for three consecutive days before each assessment) and the OAB symptom severity score (0–12) were assessed at baseline and at 3 months; adverse effects were recorded at each follow-up visit (weeks 2, 4, 8 and 12). Data were analysed in SPSS v29.0. Change from baseline was compared between groups by independent-samples t-test, and adverse effects by chi-square or Fisher’s exact test; p≤0.05 was considered significant.
Results
The groups were comparable at baseline in age (42.3±11.4 vs 43.6±12.0 years), gender, BMI and duration of symptoms (all p>0.05). At 3 months, reductions from baseline were significantly greater with solifenacin than with oxybutynin for daytime frequency (33.0% vs 24.8%), urgency (54.9% vs 35.7%), nocturia (58.4% vs 37.9%), urge incontinence (66.8% vs 43.6%) and total OAB score (56.5% vs 38.7%) (all p≤0.002). Adverse effects were less frequent with solifenacin (24.7% vs 72.9%, p
Zitieren
APA
Khan, M. A., Rathore, F. A., Nawaz, M. Z., Latif, W., Anwar, A., & Mir, D. A. (2026). Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, 22(5). https://doi.org/10.48036/hbvf7f59
Vancouver
Khan MA, Rathore FA, Nawaz MZ, Latif W, Anwar A, Mir DA. Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University. 2026;22(5). doi:10.48036/hbvf7f59
BibTeX
@article{Khan2026,
author = {Khan, Muhammad Ammar and Rathore, Farooq Azam and Nawaz, Muhammad Zeeshan and Latif, Waleed and Anwar, Aqsa and Mir, Danish Ali},
title = {Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study},
journal = {Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University},
year = {2026},
volume = {22},
number = {5},
doi = {10.48036/hbvf7f59}
}
EUVIMED